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Re. “Association of fructose
consumption and components
of metabolic syndrome in human
studies: A systematic review
and meta-analysis”
To the Editor:
We read with great interest the article by Kelishadi et al. [1]
describing a systematic review and meta-analysis of the
adverse effects of fructose on most components of the meta-
bolic syndrome (fasting blood glucose, triglycerides, high-
density lipoprotein cholesterol, and blood pressure). We are
concerned that the “before–after” comparisons favored by
the authors, the lack of adjustment for energy as a confounding
variable, and unclear statistical methods render their results
uninterpretable.
The authors chose to pool data only from the fructose-
containing intervention arm of each included trial. Without
consideration of the control arm, (that is, the counterfactual
condition, causality cannot be ascribed to fructose speciﬁcally.
As such), one cannot conclude whether the fructose interven-
tions studied would be better, the same, or worse than any
other source of calories that might replace the fructose
under the same trial conditions. The reason that randomized
controlled trials universally represent the highest level of ev-
idence to inform clinical practice guidelines and public health
policy [2,3] is that the design controls for known and un-
known confounders allowing for the isolation of the effect
of the intervention in question from other prognostic factors.
That is, it protects against important confounding from factors
that the fructose intervention shares with other dietary inter-
ventions under the same conditions. The before–after design
used by the authors provides evidence that would be consid-
ered by most systems of evidence-based medicine at the
level of a case series, rendering it not probative and “very
low quality” [3].
If these were the only data available, then we would await
higher-quality data on this question. However, the authors them-
selves have identiﬁed higher-quality data from the controlled
comparisons within these same feeding trials. If one examines
these controlled comparisons carefully, then the inferences
drawn are very different. We have published a series of Canadian
Institutes of Health Research-funded systematic reviews and
meta-analyses of controlled feeding trials of the effect of fructose
on cardiometabolic risk factors (clinical trials.gov identiﬁer,
NCT01363791). These syntheses demonstrate that when dietary
fructose is consumed in isocaloric substitution for other carbohy-
drate sources such as starch or glucose (an energy-matched
comparison between fructose and a carbohydrate comparator),
there are no deleterious effects on body weight, fasting and post-
prandial lipids, blood pressure, uric acid, glycemic control, insu-
lin, and markers of nonalcoholic fatty live disease [4–10],
although there may be a dose threshold for fasting lipids in
some subgroup analyses [10,11]. This lack of effect is true even
when fructose provides excess calories (positive energy balance),
as long as the carbohdyate comparator is matched for the excess
calories. On the contrary, consistent adverse signals are seen
when fructose is consumed in imbalanced, hypercaloric compar-
isons [4–9], in which fructose supplements control diets with
excess calories compared with the same control diets alone
without the excess calories. In the absence of an effect of fructose
in isocaloric comparisons, our syntheses suggest that the effect
of fructose seen in hypercaloric comparisons relates more to
the excess calories than the fructose. By pooling intervention
arms of fructose under isocaloric conditions (meeting energy re-
quirements) together with those under hypercaloric conditions
(exceeding energy requirements) without comparison to a con-
trol group, the systematic review and meta-analysis in question
(in which 50% of the intervention arms were hypercaloric) is un-
able to separate the effect of fructose from that of excess calories.
Taken together, these data make the case for confounding from
excess calories that can only be appreciated in controlled
comparisons.
Furthermore, the method of aggregating the study results is
unclear. In the methods section, the authors claimed to have
pooled “mean differences,” yet their forest plots report “stan-
dardized mean differences,”with no explanation for the method
of standardizing these mean differences. In the absence of a clear
congruence between methodology and results reporting, the
aggregate analysis is not meaningfully interpretable.
In conclusion, one cannot infer that fructose uniquely affects
most components of the metabolic syndrome (fasting blood
glucose, triglycerides, high-density lipoprotein cholesterol, and
blood pressure) from the present systematic review and meta-
analysis of uncontrolled comparisons. The adverse signals disap-
pear in the appropriate controlled comparisons with other
carbohydrates under calorie-matched conditions. The implica-
tion remains that fructose is no worse than other carbohydrates
likely to replace it and that any adverse effects are explained by
an imbalance in calories.
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